Dedicated oncology company, Intas Biopharmaceuticals Limited (IBPL), has come forward for a social initiative to increase awareness of scientific knowledge and information related to research & development of cancer in the community as the oncology market in India has witnessed sharp growth in recent years.

For the last two decades, Growth Factors have been increasingly used in the treatment of hematologic and oncologic diseases like neutropenia, myelodysplastic syndrome (MDS), leukemias, aplastic anaemia and bone marrow transplantation.

Commenting on the social initiative, Simon Daniel, chief executive (Marketing), IBPL, said, "There is a growing need to dissipate and inform medical fraternity and the community, at large about Growth Factors. It, so far, is an ideal treatment for haematological disorders. As much as 20 international symposiums on Growth Factors were organized in past six months by IBPL that witnessed participation of leading Oncologists and Cancer Specialists across the country. As a company, which is respected as a scientifically driven organization, IBPL is committed to channelise its efforts towards dissipating technical information and through symposiums."

Through such social initiatives, in past few months, IBPL has built a very strong scientific image in the medical fraternity across the country. The recently concluded international symposiums on Growth Factors witnessed participation of more than 200 leading cancer specialists from across the country, which is indicative of IBPL's commitment to engage medical fraternity in spreading the oncology awareness. In the month of August alone, as many as 10 symposiums were organized across the country. A series of symposiums and clinical meetings in the past few months has seen a change in the perception of organization.